STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4154 by analyst upside · 2026-06-27
TXG
10x Genomics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
-24.9%
implied upside to consensus target
Current Price $36.75
Consensus Target $27.62
Bull Target $40.0
Bear Target $20.0
Analysts Covering 13
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
4
Hold
8
Sell
0
52-Week Low $11.16
52-Week High $37.05
YTD Return +121.1%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E 183.8x
EPS (TTM) $-0.17
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $639M
Profit Margin -3.5%
52-WEEK RANGE
52-Week Low $11.16
52-Week High $37.05
Current Price $36.75
Bear Target $20.0
Bull Target $40.0
● Now $36.75 ● Target $27.62
TRADING DATA
Avg Volume 2.9M
YTD Return +121.1%
Analyst Count 13
Consensus Hold
Upside to Target -24.9%
Last Updated 2026-06-27

ANALYST SUMMARY

10x Genomics, Inc. (TXG) is currently trading at $36.75 with a Wall Street consensus price target of $27.62, which is 24.9% below the current price over the next 12 months. 13 analysts currently cover TXG, with a consensus rating of Hold - 38% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $40.0, while the most cautious has a target of $20.0.

TXG operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 121.1% year-to-date and is currently trading near the upper end of its 52-week range of $11.16 – $37.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TXG, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
JP Morgan — Reiterated
Neutral → Neutral 2026-05-12 43% win rate (7 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-20 Building track record
B of A Securities — Reiterated
Neutral → Neutral 2026-04-20 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-04-14 Building track record
Citigroup — Reiterated
Neutral → Neutral 2026-04-07 Building track record
William Blair ↑ Upgrade
Market Perform → Outperform 2026-03-31 44% win rate (9 calls)
Stifel — Reiterated
Buy → Buy 2026-03-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
20/30
Consensus clarity
19/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →